NCT03960151

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Phase II Study of Rolapitant Plus Olanzapine, Palonosetron, and Dexamethasone in Patients With Germ Cell Tumors Undergoing 5-day Cisplatin-based Chemotherapy.

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Costantine Albany · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase II study of Rolapitant plus Olanzapine, Palonosetron, and Dexamethasone in patients with germ cell tumors undergoing 5-day Cisplatin-based chemotherapy

Conditions

• Germ Cell Tumor

Interventions

Type	Name	Description
DRUG	Rolapitant	Rolapitant 180mg PO, Days 1 and 5
DRUG	Palonosetron	Palonosetron 0.25 mg IV, Days 1,3, and 5.
DRUG	Olanzapine	Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
DRUG	Dexamethasone	Dexamethasone 20 mg AM, Days 1,2 and 3

Timeline

• Start date: 2018-05-01
• Primary completion: 2021-05-01
• Completion: 2022-03-01
• First posted: 2019-05-22
• Last updated: 2019-05-22

Regulatory

• FDA-regulated drug study